Pain Epidemic (01:27)
Canadians are spending billions on cleverly marketed pain medication, while addiction to OxyContin increases.
OxyContin Introduction (01:39)
Learn how Purdue Pharma marketed the opioid as a slow release chronic pain medication.
Pain Treatment Frontier (02:31)
Vancouver doctor Roman Jovey defends his decision to advocate OxyContin to other healthcare professionals as a "safe" narcotic.
Pain Management Industry (02:04)
Purdue Pharma funded a Canadian pain treatment school and manual. Experts discuss the marketing strategy and profit motive.
OxyContin Prescriptions (02:05)
Chronic pain patient Kim describes the drug’s effect. North American sales skyrocketed in the late '90s as positive reports spread.
OxyContin Addiction (01:36)
Patient tolerance builds rapidly and doctors increase dosage. Tammy describes her attempt to stop taking the narcotic.
OxyContin Epidemic (02:39)
A Virginia substance abuse counselor describes the narcotic's rapid regional spread. Learn how the industry downplayed its addiction risk.
OxyContin Abuse (01:45)
A Lee County sheriff describes increased drug crime related to the opioid.
Purdue Damage Control (01:47)
The company initially denied OxyContin addiction, but offered Lee County money to help fix the drug problem that was spreading throughout Appalachia.
Struggling with Addiction (02:44)
Aggressive marketing, inadequate education, and regulatory failure caused widespread opioid availability. Tammy describes how OxyContin has taken over her life.
Stopping OxyContin Treatment (03:15)
By 1998, Canadian street addicts had begun injecting the pain medication. Methadone clinics help them stabilize their condition.
Opioid Dependency (03:38)
Jovey believes OxyContin benefits outweigh addiction risks. A patient says she's habituated to the medication, but not addicted.
OxyContin Profits (01:30)
U.S. salesmen were accused of understating addiction risks. By 2005, Purdue earned billions from the drug; lobbyists drowned out critics.
OxyContin Justice (01:59)
In 2007, federal prosecutors accused Purdue of lying about addiction risk. The company was fined $600 million—a moral victory that failed to recall the drug.
Targeting Doctors (03:46)
In 2007, Tammy's OxyContin addiction had driven her to steal. Purdue told Canadian physicians the U.S. lawsuit was irrelevant and increased its aggressive marketing strategy.
Public Health Reaction (02:34)
OxyContin sales reached $2.5 billion in 2010. The University of Toronto Medical School has pulled Jovey's book for opioid bias and controversial claims.
Narcotics and Pain Management (01:06)
An Ontario doctor explains why he stopped prescribing OxyContin. Despite medical caution, drug companies are producing other potentially addictive opioids.
Public Health Costs (01:35)
Jovey argues that individuals are responsible for their actions, but Methadone clinics have had to increase capacity since OxyContin was released.
Social Costs (01:56)
Kim has stopped taking OxyContin but Tammy is dependent on the opioid. A Canadian class action lawsuit has been filed against Purdue for misleading information.
Credits: Time Bomb: OxyContin Addiction (01:01)
Credits: Time Bomb: OxyContin Addiction
For additional digital leasing and purchase options contact a media consultant at 800-257-5126
(press option 3) or firstname.lastname@example.org.